In this study of new insulin users (average age, 60 years; average duration of diabetes, 8 years), treatment with glargine insulin did not increase incidence of cancers when compared with NPH users after adjusting for baseline cancer risk factors including BMI and smoking status. Here, INS is linked to diabetes mellitus.